Patents by Inventor Antonio Ricci

Antonio Ricci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20240076300
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: May 8, 2023
    Publication date: March 7, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • NEW INDAZOLE DERIVATIVES
    Publication number: 20240059692
    Abstract: The invention provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as described herein. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: November 29, 2021
    Publication date: February 22, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Ulrike OBST SANDER, Antonio RICCI
  • SUBTILISIN VARIANTS AND THEIR USE
    Publication number: 20240043897
    Abstract: The invention relates to a subtilisin BPN? variant or homologue thereof, having new mutations compared to subtilisin BPN? represented by SEQ ID NO: 2 or a homologue sequence thereof. Such mutations may occur at amino acid positions L96, D99, A223 or S224. The invention further relates to a method for enzymatically synthesizing a peptide by coupling peptide fragments, wherein the coupling is catalyzed by the subtilisin BPN? variant or homologue thereof.
    Type: Application
    Filed: February 9, 2022
    Publication date: February 8, 2024
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Timo NUIJENS, Jurgen MATEMAN, Rowin DE VISSER, Walter CABRI, Kerstin WALLRAVEN, Elvira WIJKER, Antonio RICCI, Ana TOPLAK
  • PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES
    Publication number: 20240025883
    Abstract: Compounds having the general formula I wherein R1, R2, R3, R4, X1 and X2 are as described herein, composition including the compounds and methods of using the compounds for treatment of GPR17-mediated diseases.
    Type: Application
    Filed: August 24, 2023
    Publication date: January 25, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Luca GOBBI, Wolfgang GUBA, Dmitry MAZUNIN, Emmanuel PINARD, Antonio RICCI
  • NEW INDAZOLE DERIVATIVES
    Publication number: 20240018154
    Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R4 and A are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: November 29, 2021
    Publication date: January 18, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Christa Ulrike OBST-SANDER, Antonio RICCI
  • NEW INDAZOLE ACETYLENE DERIVATIVES
    Publication number: 20240002390
    Abstract: The invention provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R2?, R3, R4 and R5 are as described herein. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: November 29, 2021
    Publication date: January 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Ulrike OBST SANDER, Antonio RICCI
  • 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds
    Patent number: 11708354
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: July 25, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • Amino deprotection using 3-(diethylamino)propylamine
    Patent number: 11692007
    Abstract: The invention provides a method for the cleavage of Fmoc group characterized by using a solution comprising 3-(diethylamino)propylamine. In particular, it provides a method for the preparation of peptides in solid phase wherein Fmoc protected amino acids are used and the Fmoc group is cleaved by a solution comprising 3-(diethylamino)propylamine.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: July 4, 2023
    Assignees: Alma Mater Studiorum—Università di Bologna, Fresenius Kabi IPSUM S.r.l.
    Inventors: Giulia Martelli, Paolo Cantelmi, Alessandra Tolomelli, Chiara Palladino, Lucia Ferrazzano, Walter Cabri, Marco Macis, Angelo Viola, Antonio Ricci
  • Isoindolinone and indazole compounds for the degradation of EGFR
    Patent number: 11673902
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: June 13, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20230110648
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 13, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • EGFR INHIBITORS
    Publication number: 20230057891
    Abstract: The application provides a compound having the general formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
  • EGFR INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20230054473
    Abstract: The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: February 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • EGFR INHIBITORS
    Publication number: 20230034696
    Abstract: The application provides a compound having the general formula (I) or a pharmaceutically acceptable salt thereof, compositions including the compound and methods of using the compound. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 2, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
  • Process for the preparation of high purity glucagon
    Patent number: 11566058
    Abstract: The present invention provides an improved process for the preparation of high purity glucagon comprising the use of Xmb-protected amino acids, wherein may Xmb include, e.g., 2,4,6-trimethoxybenzyl, 2,4-dimethoxybenzyl, or 2-hydroxy-4-methoxybenzyl. The process also comprises the use of building blocks such as pseudoprolines to avoid aggregation and obtain the product in high yield and purity.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: January 31, 2023
    Assignee: Fresenius Kabl iPSUM S.R.L.
    Inventors: Andrea Orlandin, Antonio Ricci, Walter Cabri, Steve McIntyre, Alex Saunders
  • PROCESS FOR THE MANUFACTURE OF GLUCAGON
    Publication number: 20220324936
    Abstract: The present invention provides an improved process for the preparation of glucagon, comprising the coupling of an N-terminal tetramer fragment with a C-terminal peptide, comprising at least one pseudoproline. The process is very efficient in avoiding aggregation and obtaining the desired product in high yield and purity.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 13, 2022
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Andrea ORLANDIN, Antonio RICCI, Walter CABRI
  • EGFR INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20220315593
    Abstract: The application relates to 6 specific heterocyclic compounds, pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • EGFR INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20220315592
    Abstract: The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • NEW EGFR INHIBITORS
    Publication number: 20220315591
    Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Roger David NORCROSS, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • NEW EGFR INHIBITORS
    Publication number: 20220315577
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and R10 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • Process for the manufacture of GLP-1 analogues
    Patent number: 11396533
    Abstract: The present invention provides a process for the manufacture of GLP-1 analogues with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a C-terminal pseudoproline fragment A with a fragment B bound to a solid support, followed by deprotection and cleavage from the support and final purification to yield the desired peptide. The invention further provides intermediates useful in the manufacturing process.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: July 26, 2022
    Assignee: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Giuseppina Maria Incisivo, Andrea Orlandin, Antonio Ricci, Ivan Guryanov, Walter Cabri